Publications & Presentations


June 2019 | ARQ 092 / Rare Disease
An Open-label, Phase 1/2 Study of Miransertib (ARQ 092), an Oral Pan-AKT Inhibitor, in Patients (pts) with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS): Study Design and Preliminary Results (NCT03094832)
European Society of Human Genetics Conference (ESHG)
Presented by: C. Leoni, et.al

June 2019 | ARQ 531 / Clinical
A Phase 1 Dose Escalation Study of ARQ 531 in Patients With Relapsed or Refractory B-cell Lymphoid Malignancies
24th Congress of the European Hematology Association (EHA)
Presented by: J. Woyach, et al.

February 2019 | ARQ 092 / Rare Disease
Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
The American Journal of Human Genetics
Presented by: Keppler-Noreuil, et al.

December 2018 | ARQ 531 / Clinical
A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies
2018 American Society of Hematology (ASH) Annual Meeting
Presented by: J. Woyach, et al.

November 2018 | ARQ 751
Miransertib and ARQ 751 exhibit superior cell-death-inducing properties compared to other AKT inhibitors and can overcome resistance to other allosteric AKT inhibitors
30th EORTC/AACR/NCI Symposium
Presented by: E. Kostaras, et al.

November 2018 | ARQ 751
A Phase 1 Dose Escalation Study of ARQ 751 in Adult Patients with Advanced Solid Tumors with AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations
30th EORTC/AACR/NCI Symposium
Presented by: S. Pant, et al.

November 2018 | ARQ 751
Combination of the AKT inhibitor ARQ 751 with Immune Checkpoint Inhibitor and Other Therapeutic Agents
30th EORTC/AACR/NCI Symposium
Presented by: Y.Yu, et al.

October 2018 | ARQ 092 / Rare Disease
An Open-Label, Phase 1/2 Study of Miransertib (ARQ 092), an Oral pan-AKT Inhibitor, in Patients with PIK3CA-Related Overgrowth Spectrum (PROS): Preliminary Results
American Society of Human Genetics (ASHG) 2018 Annual Meeting
Presented by: A. Bartuli, et al.

October 2018 | ARQ 092 / Rare Disease
Severe PI3Kinase Overgrowth Syndrome Treated with the AKT Inhibitor Miransertib
American Society of Human Genetics (ASHG) 2018 Annual Meeting
Presented by: A.D. Irvine, et al.

October 2018 | ARQ 092 / Rare Disease
Personalized Medicine in Rare Diseases and Cancer: A Case Report of a Lasting Response in a Young Teenage Patient with Proteus Syndrome and Secondary Ovarian Cancer
American Society of Human Genetics (ASHG) 2018 Annual Meeting
Presented by: C. Leoni, et al.

August 2018 | ARQ 531 / Pre-clinical
The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter’s Transformation
Cancer Discovery
Presented by: J. Woyach, S. Reiff, et. al.

June 2018 | ARQ 531 / Clinical
A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies
23nd Congress of the European Hematology Association (EHA)
Presented by: J. Woyach, et al.

April 2018 | ARQ 092 / Oncology
A phase 1b study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial and ovarian cancer
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: V. Makker, et al.

April 2018 | ARQ 751
Results of A Phase 1 Dose Escalation Study of ARQ 751 in Adult Subjects with Advanced Solid Tumors with AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: S. Pant, et al.

April 2018 | ARQ 092 / Pre-clinical
Combinations of Imatinib Mesylate with AKT inhibitor (miransertib, ARQ 751) or FGFR inhibitor (derazantinib) show synergy in GIST cell lines and pre-clinical models
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: M. Kozinova, et al.

April 2018 | ARQ 531 / Pre-clinical
In Vitro and In Vivo Effect of ARQ 531 on Trk Family Kinases
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: Y. Yu, et al.

April 2018 | ARQ 531 / Pre-clinical
ARQ 531, a Reversible BTK Inhibitor, Exhibits Potent Anti-tumor Activity in Ibrutinib-Resistant Diffuse Large B-cell Lymphoma
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: S. Eathiraj, et al.

April 2018 | ARQ 531 / Clinical
ARQ 531, a Novel and Reversible Inhibitor of Bruton’s Tyrosine Kinase, Displays Favorable Oral Bioavailability and Exposure in Patients with B-cell Malignancies
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: T. Hall, et al.

April 2018 | ARQ 531 / Pre-clinical,  ARQ 092 / Pre-clinical
In Vitro and In Vivo Combination of Miransertib (ARQ 092) with Anti-PD-1 Antibody, Trametinib, Lapatinib, Trastuzumab, Paclitaxel and ARQ 531
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: Y. Yu, et al.

April 2018 | ARQ 087 / iCCA
Derazantinib (ARQ 087) Pharmacodynamics: Alterations in FGF19/21/23 and Phosphate in Patients with Cholangiocarcinoma
2018 American Association for Cancer Research (AACR) Annual Meeting
Presented by: T. Hall, et al.

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300